Related Experiment Video
Updated: Oct 27, 2025
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.2K
Nanomaterials for Modulating the Aggregation of β-Amyloid Peptides
Yaliang Huang1,2, Yong Chang2, Lin Liu2
1Hunan Provincial Key Laboratory of Micro & Nano Materials Interface Science, College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, China.
Molecules (Basel, Switzerland)
|July 24, 2021
Summary
Nanomaterials offer a novel approach to combat Alzheimer's disease (AD) by inhibiting and dissociating amyloid-beta (Aβ) aggregation. This review explores nanomaterial-based strategies for developing effective AD therapeutics and theranostics.
Area of Science:
- Neuroscience
- Materials Science
- Biochemistry
Background:
- Alzheimer's disease (AD) is characterized by the aggregation of amyloid-beta (Aβ) peptides in the brain.
- Inhibiting and dissociating Aβ aggregation are key therapeutic strategies for AD.
- Traditional therapeutic agents for AD often have limitations.
Purpose of the Study:
- To provide an overview of nanomaterials used for modulating Aβ aggregation.
- To discuss the mechanisms involved in nanomaterial-based Aβ aggregation inhibition.
- To highlight the potential of nanomaterials in AD theranostics.
Main Methods:
- Literature review of recent advancements in nanomaterials for AD treatment.
- Analysis of synergistic effects between nanomaterials and traditional agents.
- Discussion of underlying mechanisms of Aβ aggregation modulation.
Main Results:
- Nanomaterials can overcome the limitations of traditional AD agents.
- Synergistic effects enhance the efficiency of therapeutic strategies.
- Nanomaterials offer promising platforms for AD treatment and theranostics.
Conclusions:
- Nanomaterials represent a significant advancement in the development of anti-amyloid agents.
- Understanding nanomaterial-based modulation of Aβ aggregation is crucial for future AD therapies.
- This field offers new insights into exploring novel therapeutic tactics for AD.
Related Concept Videos
03:03Amyloid Fibrils
10.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.9K
03:03Amyloid Fibrils
6.0K
6.0K